Date: 2014-07-16
Type of information: Production agreement
Compound: cancer immunotherapy HER-Vaxx
Company: Mymetics (Switzerland) Imugene (Australia)
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing production
Action mechanism:
Disease:
Details: * On July 16, 2014, Mymetics announced that it has signed an exclusive agreement with Imugene, an Australian based biopharmaceutical company, to manufacture and develop its cancer immunotherapy HER-Vaxx, which is planned to enter into a PhaseI/II clinical trial in 2015. Mymetics will use its strong experience and specialist know-how in virosome based vaccines and integrating antigens in viral membranes to manufacture the Imugene HER-Vaxx cancer immunotherapy vaccine candidate.
Financial terms:
Latest news:
